The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas.
作者信息
Hahn Andrew W, Agarwal Neeraj
机构信息
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
出版信息
Cancer Treat Res Commun. 2020;24:100190. doi: 10.1016/j.ctarc.2020.100190. Epub 2020 Jul 4.
Abstract
摘要
相似文献
1
The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas.晚期前列腺癌、膀胱癌和肾细胞癌迅速演变的治疗格局。
Cancer Treat Res Commun. 2020;24:100190. doi: 10.1016/j.ctarc.2020.100190. Epub 2020 Jul 4.
2
PARP inhibitors in castration-resistant prostate cancer.聚腺苷二磷酸核糖聚合酶抑制剂在去势抵抗性前列腺癌中的应用。
Cancer Treat Res Commun. 2020;24:100199. doi: 10.1016/j.ctarc.2020.100199. Epub 2020 Jul 22.
3
Neoadjuvant PARPi for urothelial carcinoma: between lifeline and desperation.用于尿路上皮癌的新辅助聚（ADP-核糖）聚合酶抑制剂：在生命线与绝望之间
Future Oncol. 2021 Sep;17(25):3281-3283. doi: 10.2217/fon-2021-0443. Epub 2021 Jul 21.
4
Immunotherapy for genitourinary tumors.泌尿生殖系统肿瘤的免疫治疗。
Int J Urol. 2019 Mar;26(3):326-333. doi: 10.1111/iju.13902. Epub 2019 Feb 1.
5
Switch maintenance therapy for advanced bladder cancer: A paradigm shift in 2020.晚期膀胱癌的转换维持治疗：2020年的范式转变。
Cancer Treat Res Commun. 2020;24:100202. doi: 10.1016/j.ctarc.2020.100202. Epub 2020 Jul 31.
6
DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.泌尿生殖系统恶性肿瘤中的DNA损伤修复基因改变
Eur Surg Res. 2022;63(4):155-164. doi: 10.1159/000526415. Epub 2022 Aug 9.
7
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.卡博替尼在骨转移性肾细胞癌和去势抵抗性前列腺癌中的生物学问题。
Future Oncol. 2018 Oct;14(25):2559-2564. doi: 10.2217/fon-2018-0158. Epub 2018 Aug 24.
8
Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.接受 PD-1/PD-L1 抑制剂治疗的尿路上皮癌或肾细胞癌患者的超进展性疾病。
Clin Genitourin Cancer. 2020 Apr;18(2):e122-e133. doi: 10.1016/j.clgc.2019.09.009. Epub 2019 Sep 26.
9
Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?转移性去势抵抗性前列腺癌的治疗：PARP 抑制剂是否正在改变治疗模式？
Anticancer Res. 2021 Oct;41(10):4687-4695. doi: 10.21873/anticanres.15282.
10
PARP inhibition in castration-resistant prostate cancer.去势抵抗性前列腺癌中的聚（ADP-核糖）聚合酶抑制作用
Future Oncol. 2016 Mar;12(5):577-80. doi: 10.2217/fon.16.1. Epub 2016 Jan 21.
本文引用的文献
1
Olaparib for Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
2
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.随机、双盲、II 期研究：一线化疗后维持治疗帕博利珠单抗对比安慰剂在转移性尿路上皮癌患者中的应用。
J Clin Oncol. 2020 Jun 1;38(16):1797-1806. doi: 10.1200/JCO.19.03091. Epub 2020 Apr 9.
3
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.PARP 抑制剂在治疗转移性去势抵抗性前列腺癌中的临床开发。
Cells. 2019 Aug 9;8(8):860. doi: 10.3390/cells8080860.
4
Integrative Clinical Genomics of Advanced Prostate Cancer.晚期前列腺癌的综合临床基因组学
Cell. 2015 Jul 16;162(2):454. doi: 10.1016/j.cell.2015.06.053.
5
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.转移性前列腺癌男性患者的遗传性DNA修复基因突变
N Engl J Med. 2016 Aug 4;375(5):443-53. doi: 10.1056/NEJMoa1603144. Epub 2016 Jul 6.
Zotero 插件